Optimizing Phosphopeptide Structures That Target 14-3-3ε in Cutaneous Squamous Cell Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• 14-3-3ε protein is implicated in various cancers, including cutaneous squamous cell carcinoma (cSCC), by promoting cell survival and invasion.
• In cSCC, 14-3-3ε overexpression and cytoplasmic mislocalization lead to the suppression of apoptosis through interaction with CDC25A.
• Inhibiting the 14-3-3ε - CDC25A interaction presents a promising therapeutic target for inducing apoptosis in cSCC.

Approach:

• The study optimized a previously designed phosphopeptide inhibitor (pT) targeting the 14-3-3ε - CDC25A interaction.
• Peptide analogs were designed by truncating the pT sequence and introducing specific amino acid substitutions.
• Molecular dynamics simulations and biophysical methods were employed to assess the binding affinities of the designed peptides to 14-3-3ε.

Key Points:

• A shortened peptide analog, pT(502-510), demonstrated significant binding affinity to 14-3-3ε with a K_D of 45.2 nM.
• A further modification, substituting Glycine with Phenylalanine at position 510, enhanced the binding affinity to 22.0 nM.
• These optimized peptide analogs effectively inhibit the 14-3-3ε - CDC25A interaction.

Conclusions:

• The developed peptide analogs exhibit high affinity for 14-3-3ε, indicating their potential as inhibitors.
• These findings suggest that the designed peptides could serve as novel therapeutic agents for cSCC by inducing apoptosis.
• Further investigation into these peptide analogs may lead to new treatment strategies for cutaneous squamous cell carcinoma.